FDA approval expands range of Metadate (methylphenidate) dosages

Article

The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Medadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).

The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Metadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).

The capsules are already available in 10 mg, 20 mg, and 30 mg strengths, with a recommended starting dose of 20 mg once daily.

"The new strengths will allow for the full range of immediate-release doses (30% of the total) from a single capsule," said James M. Swanson, MD, PhD, professor of pediatrics at the University of California, Irvine. "The addition of these doses will allow physicians greater flexibility in tailoring a treatment regimen to the individual needs and responses of each patient."

Recent Videos
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Discussion: AAP's opioid for acute pain clinical practice guideline with Jessica Spruit, DNP
Bobbie Monaco, MSN, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
© 2025 MJH Life Sciences

All rights reserved.